<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022968</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO14-CH/TEPTAU</org_study_id>
    <nct_id>NCT03022968</nct_id>
  </id_info>
  <brief_title>Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)</brief_title>
  <acronym>TEPTAU</acronym>
  <official_title>Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently revised Alzheimer Disease (AD) diagnostic1described nonamnestic presentations: 1/
      language presentation (logopenic progressive aphasia) 2/ visuospatial presentation (posterior
      cortical atrophy or PCA) and 3/ executive dysfunction. AD pathological changes may precede
      the clinical diagnosis of dementia of AD type for a while2. Biomarkers have been developed:
      biomarkers of brain amyloid-beta (Aß) (CerebroSpinal Fluid CSF concentration ßamyloid,
      molecular imaging with amyloid targeted PET ligands), biomarkers of neural degeneration (MRI
      hippocampal volume, regional metabolism as assessed by PET with [18F]-FDG) and may be used to
      made early detection of the neuropathology associated with AD Even if CSF biomarkers (tau,
      p-tau and β amyloïd are interesting to improve diagnosis of AD, they cannot provide
      topographic information. PET tau imaging seems to be promise to evaluate quantitative and
      spatial assessment of tau lesions both in AD and fronto-temporal lobar dementia.

      The hypothesis of the research is that it exists a different regional pattern of tracer
      retention across brain regions according to clinical symptoms : temporal for logopenic
      aphasia and occipital for posterior cortical atrophy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tau density on PET imaging</measure>
    <time_frame>3 months</time_frame>
    <description>density pattern of aggregated tau using tau targeting PET imaging with [18F]-T807, in Standardized uptake value (SUV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tau distribution on PET imaging</measure>
    <time_frame>3 months</time_frame>
    <description>distribution pattern of aggregated tau using tau targeting PET imaging with [18F]-T807, in Standardized uptake value (SUV)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>p-tau CSF biomarkers</measure>
    <time_frame>inclusion</time_frame>
    <description>p-tau dosing in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>βamyloid CSF biomarkers</measure>
    <time_frame>inclusion</time_frame>
    <description>βamyloid dosing in pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive profile with Hamilton depression scale (MADRS)</measure>
    <time_frame>inclusion</time_frame>
    <description>neuropsychological score of Hamilton depression scale (MADRS) on 30 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive profile with Mini mental state evaluation (MMSE)</measure>
    <time_frame>inclusion</time_frame>
    <description>neuropsychological score of Mini mental state evaluation (MMSE) on 60 points</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Benson's Disease</condition>
  <arm_group>
    <arm_group_label>Alzheimer disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]T807 PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benson disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]T807 PET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[18F]T807 PET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]T807 PET</intervention_name>
    <description>Imaging with [18F]T807 PET</description>
    <arm_group_label>Alzheimer disease</arm_group_label>
    <arm_group_label>Benson disease</arm_group_label>
    <arm_group_label>Healthy volunteer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 years old and more

          -  native langage: french

          -  study level upper (or equal) than 7 year (considering first year of grammar-school as
             start)

          -  correct sensory abilities (auditive device allowed) for tests

          -  affiliation to social security

          -  Informed, written consent form

          -  for Alzheimer disease group: people with Alzheimer Disease defined as National
             Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the
             Alzheimer's Disease and Related Disorders Association (ADRDA) standards: Light to mild
             AD defined by Mini-Mental State Examination (MMSE) score between 15 and 25 (included)

          -  for Benson disease group: Benson disease following Mendez et al (2002) and Tang Wai et
             al (2004) criteria

          -  for healthy volunteer group: normal MMS score (more than 26 for bachelor level)

        Exclusion Criteria:

          -  history of disease with consequances on cognitive functioning (tumor, stroke, head
             trauma, etc.), cerebral surgery

          -  use of alchohol and/or drug

          -  anormalies in neurological exam (focal deficit) not included in the classic symptoms

          -  contraindication to magnetic resonance imaging (RMI)

          -  contraindication to PET: people with prolongation of QT interval or taking medication
             that can lead to &quot;torsades de pointe&quot;.

          -  claustrophobia

          -  person with legal protection

          -  exclusion period because of participation to another experimental protocol and actual
             participation to an experimental protocol

          -  pregnant or lactating woman or able to procreate and without contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maria-Joao Santiago-Ribeiro, PhD</last_name>
    <phone>+33247479729</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Roussel</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria-Joao Santiago-Ribeiro</last_name>
      <phone>+33247479729</phone>
    </contact>
    <investigator>
      <last_name>Maria-Joao Santiago-Ribeiro, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valerie Gissot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent Camus, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emilie Beaufils, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

